跳至主要内容
临床试验/ACTRN12608000573358
ACTRN12608000573358已完成4 期

A randomised controlled trial to investigate whether an individualised dosage of enoxaparin reduces the incidence of minor and major bleeding when compared to conventional dosing in patients receiving treatment doses of enoxaparin for cardiovascular disease

School of Pharmacy0 个研究点目标入组 22 人开始时间: 2008年11月12日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
22

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • All patients admitted for treatment with enoxaparin who are likely to require treatment for at least 48 hours are eligible for inclusion into the study.

排除标准

  • Patients who are pregnant; less than 18 years old; have received warfarin in the past 7 days or heparin therapy (unfractionated heparin 'UFH' or low-molecular weight heparin 'LMWH') in the last day; have an international normalised ratio 'INR' > 1.2 or an Activated Partial Thromboplastin Time 'APTT' > 60 seconds at the time of recruitment; or an estimated creatinine clearance less than 10 ml/min (using the Cockcroft and Gault equation calculated based on lean body weight).

研究者

相似试验